Skip to main content

Table 2 Adjusted risk for secondary outcomes for subjects treated with 4 g/acetaminiophen/day

From: A randomized, placebo-controlled trial to determine the course of aminotransferase elevation during prolonged acetaminophen administration

 

Extended dosing

ALT increase > 10 IU/L

ALT increase >50% above baseline

Variable

Odds ratio

95% Confidence interval

Odds ratio

95% Confidence interval

Odds ratio

95% Confidence interval

Female (vs Male)

1.47

0.64 to 3.73

1.03

0.53 to 2.03

1.21

0.61 to 2.39

Race

      

 Caucasian

1.0

Ref

1.0

Ref

1.0

Ref

 Black

1.71

0.47 to 6.26

3.56

1.02 to 12.45

1.80

0.54 to 5.99

 Hispanic

1.86

0.79 to 4.40

1.45

0.66 to 3.2

1.67

0.75 to 3.69

 Other

1.85

0.58 to 5.91

1.40

0.50 to 3.96

1.81

0.63 to 5.24

Age (per yr)

1.01

0.98 to 1.04

1.02

0.99 to 1.04

1.02

1.00 to 1.05

Baseline ALT (Per IU/L)

1.03

0.98 to 1.08

1.01

0.97 to 1.05

0.96

0.92 to1.00

BMI

0.98

0.93 to 1.04

0.98

0.93 to 1.03

0.99

0.94 to 1.04

No ethanol use

1.81

0.81 to 4.1

0.90

0.42 to 1.92

0.89

0.42 to 1.88